Boehringer wins accelerated approval for first-line use of lung cancer drug
Lei Lei Wu / endpoints - The FDA greenlit an expanded label for Boehringer Ingelheim’s lung cancer drug Hernexeos, marking the first use of the Commissioner's National Priority Voucher for a new indication. Boehringer won an accelerated
AI Summary: Regulators accelerated approval of Boehringer Ingelheim’s lung cancer therapy for first‑line use, leveraging a priority review mechanism that sped the timeline. The label expansion places the drug into earlier treatment settings, reflecting promising data and the efficiency (and occasional controversy) of voucher‑assisted regulatory pathways.
Related Stories
FDA links eight deaths to Amgen’s Tavneos; scrutiny intensifies / 3 months
FDA partially halts cancer trial following patient death and safety events / 4 months
FDA launches individualized therapy framework for ultra-rare diseases / 4 months
FDA makes one pivotal trial the default for drug approvals / 4 months
FDA refuses to review Moderna mRNA flu vaccine application / 5 months
FDA rejects Atara cell therapy for Epstein–Barr virus complications / 5 months
FDA clears first new sunscreen ingredient in two decades / 28 days
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Drug Pricing, Cancer Research, CDC, Infant Health and look for the RSS link.
StackHealth Time Machine